文献速递骨质疏松与代谢性骨病

阿仑膦酸钠与雷洛昔芬在地舒单抗后的比较(CARD)研究:一项疗效比较试验

The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial.
PubMed 文献 · Osteoporos Int · 2023-10-06

该开放标签随机对照试验将51名骨折风险增加的绝经后女性随机分配至接受12个月地舒单抗60mg每6个月一次后,再接受12个月阿仑膦酸钠70mg每周一次或雷洛昔芬60mg每日一次。结果显示,地舒单抗停药后,阿仑膦酸钠组骨转换标志物持续抑制,而雷洛昔芬组逐渐回升至基线;阿仑膦酸钠组各部位骨密度维持,雷洛昔芬组脊柱和全髋骨密度显著下降。结论提示地舒单抗治疗一年后,阿仑膦酸钠比雷洛昔芬更能维持骨转换抑制和骨密度增益。

要点

  • 地舒单抗停药后序贯阿仑膦酸钠可维持骨转换抑制和骨密度增益。
  • 序贯雷洛昔芬者脊柱和全髋骨密度显著下降,但股骨颈和桡骨远端稳定。
  • 阿仑膦酸钠在维持骨密度方面优于雷洛昔芬。

核心结论

  • 结果提示地舒单抗治疗一年后,序贯阿仑膦酸钠一年比雷洛昔芬更能维持骨转换抑制和骨密度增益。

研究设计与样本

  • 开放标签随机对照试验,纳入51名骨折风险增加的绝经后女性,等概率随机接受12个月地舒单抗60mg每6个月一次,随后12个月阿仑膦酸钠70mg每周一次或雷洛昔芬60mg每日一次。

主要发现

  • 地舒单抗停药后,序贯阿仑膦酸钠组血清骨转换标志物持续抑制,序贯雷洛昔芬组逐渐回升至基线。
  • 序贯阿仑膦酸钠组地舒单抗诱导的骨密度增益在所有部位均维持;序贯雷洛昔芬组脊柱骨密度下降2.0%(95%CI -3.2至-0.8,P=0.003),全髋骨密度下降1.2%(95%CI -2.1至-0.4,P=0.008),股骨颈和桡骨远端稳定且各部位均高于原始基线。
  • 序贯雷洛昔芬组脊柱和全髋骨密度下降与序贯阿仑膦酸钠组相比有显著差异,股骨颈和桡骨远端无显著差异。

关键数值与推荐

  • 地舒单抗60mg每6个月一次,共12个月。
  • 阿仑膦酸钠70mg每周一次,共12个月。
  • 雷洛昔芬60mg每日一次,共12个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Denosumab discontinuation results in accelerated bone remodeling, decreased bone mineral density (BMD), and an increased risk of multiple vertebral fractures. Bisphosphonates are at least partially effective at inhibiting these consequences but there have been no randomized clinical trials assessing the efficacy of alternative antiresorptives. PURPOSE: The aim of this study was to evaluate the comparative efficacy of alendronate and the SERM, raloxifene, in preventing the post-denosumab high-turnover bone loss. METHODS: We conducted an open-label randomized controlled trial in which 51 postmenopausal women at increased risk of fracture were randomized with equal probability to receive 12-months of denosumab 60-mg 6-monthly followed by 12-months of either alendronate 70-mg weekly or raloxifene 60-mg daily. Serum bone remodeling markers were measured at 0,6,12,15,18, and 24 and areal BMD of the distal radius, spine, and hip were measured at 0,12,18 and 24 months. RESULTS: After denosumab discontinuation, serum markers of bone remodeling remained suppressed when followed by alendronate, but gradually increased to baseline when followed by raloxifene. In the denosumab-to-alendronate group, denosumab-induced BMD gains were maintained at all sites whereas in the denosumab-to-raloxifene group, BMD decreased at the spine by 2.0% (95% CI -3.2 to -0.8, P = 0.003) and at the total hip by 1.2% (-2.1 to -0.4%, P = 0.008), but remained stable at the femoral neck and distal radius and above the original baseline at all sites. The decreases in spine and total hip BMD in the denosumab-to-raloxifene group (but not the femoral neck or distal radius) were significant when compared to the denosumab-to-alendronate group. CONCLUSIONS: These results suggest that after one year of denosumab, one year of alendronate is better able to maintain the inhibition of bone remodeling and BMD gains than raloxifene.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Ramchand SK, Tsai JN, Lee H, et al. The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial. Osteoporos Int. 2023. PMID: 37798320. doi:10.1007/s00198-023-06932-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。